Business
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients
About this update from Nuvalent, Inc.
[{"type":"text","content":"Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC \nEnrollment progressing in ALKOVE-1 Phase 1/2 trial with parallel-lead candidate, NVL-655, for ALK-positive NSCLC \nNVL-330 demonstrates potency and selectivity for HER2 Exon 20 insertion mutations, and brain penetration in preclinical studies\n$264.5 million upsized public offering along with cash, cash equivalents, and marketable securities as of September 30, 2022 expected to extend operating runway into second half of 2025\nCAMBRIDGE, Mass., Nov. 10, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent business and pipeline progress and third quarter 2022 financial results.\n\n \n \n \n \n \n \n\n \n\"This has been a transformational year for Nuvalent, exemplified by the totality of the data presented at EORTC-NCI-AACR (ENA) which showcased the rapid and meaningful progress our team has made towards our mission of delivering a portfolio of precisely targeted therapies for patients with cancer,\" said James Porter, Ph.D., Chief Executive Officer at Nuvalent. \"Importantly, we reported preliminary data from the Phase 1 portion of our ARROS-1 study for NVL-520 in heavily pre-treated patients with ROS1-positive non-small cell lung cancer (NSCLC), representing the first clinical proof-of-concept data from our portfolio. We believe these data support the planned investigation of NVL-520 in the treatment-naïve setting as part of the next phase of our study and continue to support the best-in-class potential of NVL-520 for the treatment of patients with ROS1-positive NSCLC. We look forward to engaging with regulators to discuss the recommended Phase 2 dose and beginning the Phase 2 portion of the ARROS-1 trial.\"\nDr. Porter continued, \"Furthermore, the learnings from our work on NVL-520 and the ARROS-1 trial have directly informed our parallel lead program, NVL-655, and the design of the ALKOVE-1 trial for patients with ALK-positive NSCLC, as well as our earlier-stage pipeline including our third development candidate, NVL-330. Data supporting the differentiated preclinical profiles of NVL-655...